Kura Oncology Inc. (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

Separately, Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $16.00 price target on shares of Kura Oncology in a report on Tuesday, June 21st.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/kura-oncology-inc-kura-upgraded-by-zacks-investment-research-to-hold.html

Kura Oncology (NASDAQ:KURA) opened at 5.56 on Wednesday. The company has a 50-day moving average of $6.13 and a 200 day moving average of $4.17. The company’s market cap is $104.21 million. Kura Oncology has a 52-week low of $2.50 and a 52-week high of $25.00.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. Equities research analysts predict that Kura Oncology will post ($1.58) EPS for the current year.

A hedge fund recently bought a new stake in Kura Oncology stock. Alethea Capital Management LLC bought a new position in Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned about 0.34% of Kura Oncology at the end of the most recent reporting period. 43.63% of the stock is currently owned by institutional investors.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

5 Day Chart for NASDAQ:KURA

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.